Lexicon Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

• Lexicon Pharmaceuticals Inc LXRX.OQ reported a quarterly adjusted loss of 7 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -20 cents. The mean expectation of four analysts for the quarter was for a loss of 10 cents per share. Wall Street expected results to range from -12 cents to -8 cents per share.

• Revenue rose 11.7% to $1.26 million from a year ago; analysts expected $1.41 million.

• Lexicon Pharmaceuticals Inc's reported EPS for the quarter was a loss of 7 cents​.

• The company reported a quarterly loss of $25.3 million.

• Lexicon Pharmaceuticals Inc shares had risen by 46.2% this quarter and lost 8.7% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 20.9% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Lexicon Pharmaceuticals Inc is $1.20

This summary was machine generated from LSEG data May 13 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)